Pharmacological deactivation of ULK1/2 using a small-molecule kinase inhibitor SBI-0206965 synergizes with hexokinase I inhibitor 2-deoxyglucose (2-DG) and hexokinase II inhibitor 3-bromopyruvate (3-BP) to suppress tumor development in both PDAC cell- and patient-derived xenograft models. Here, ULK1 is linked to neoplasm.